TACE plus camrelizumab and rivoceranib prolongs progression-free survival versus TACE alone in unresectable HCC
Combination therapy extends time without cancer progression in liver cancer patients
This phase II randomized trial in 200 patients with unresectable hepatocellular carcinoma compared TACE plus camrelizumab and rivoceranib (T…
Adding two new drugs to standard liver cancer treatment helped patients go 10.8 months longer without their cancer getting worse compared to…
Guideline reviews perioperative immunotherapy for hepatocellular carcinoma after resection or ablation
A New Strategy Emerges to Stop Liver Cancer From Coming Back
A guideline reviews perioperative immunotherapy for hepatocellular carcinoma after resection or ablation. Adjuvant atezolizumab plus bevaciz…
Doctors are finding smarter ways to use the body’s own immune system around the time of surgery to give patients with liver cancer a better …